Omicron Variant: Letter to our customers

To Our Valued Seegene Customer,

The World Health Organization has identified the Omicron variant (B.1.1.529) as the latest strain of the SARS-CoV-2 virus to be designated as a Variant of Concern.


As the first cases are emerging in the US, Seegene confirms that the performance or quality of the Seegene EUA Allplex™ 2019-nCoV Assay is not impacted by either the Omicron variant or the Delta variants.


Seegene has conducted an in-silico analysis of this Variant of Concern, indicating that our assay can amplify and detect 100% of the currently available SARS-CoV-2 Omicron sequences.

For more details, read the complete Seegene statement on testing for the COVID-19 Omicron variant here:

SEEGENE’S STATEMENT ON OMICRON VARIANT TESTING

As a leading molecular diagnostic company, Seegene continues to monitor new activity connected to COVID-19 Variants of Concern to ensure our assays’ integrity and excellent performance.

Furthermore, Seegene has developed a series of Research Use Only assays to identify some mutations consistent with Omicron, and differentiate between Omicron and other variants such as the Delta variants.

Novaplex™ SARS-CoV-2 Variants Assays

Seegene variants assay chart depicting Seegene assays and the respective mutations that they cover for COVID-19 variants such as Omicron, Delta etc.

Please feel free to contact Seegene Technologies if you have any further questions.